SUMMARY. A random population was screened for abnormal dibucaine and fluoride numbers (DN & FN) to find some common mutations in butyryicholinesterase (BCHE) gene. 01'2375 unrelated individuals, 10 were found to have low DN and FN and were selected for further studies. DNA analysis of these hypocholinesterasemics revealed that seven patients were heterozygous for missense mutation at codon 330 (TTA to ATA; BCHE*330l). The frequency of BCHE*3301 mutation was calculated to be at least 0·29% among the Japanese. On the other hand, two novel mutations were found in three families and two individuals including probands whose enzyme activity was very low (silent gene). Polymerase chain reaction and single stranded conformation polymorphism (PCR-SSCP) and restriction fragment length polymorphism (PCR-RFLP) were used for identification of the common and known mutation types such as BCHE*250P (ACT to CCT), BCHE*365R (GGA to CGA), and BCHE*539T(GCA to ACA; K-polymorphism), whereas PCR-SSCP was used in combination with direct DNA sequencing for new mutations like BCHE*446V (TTT to GTT) and BCHE*451X (GAA to TAA).
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Genetic variants of human butyrylcholinesterase (EC 3.1.1.8; pseudocholinesterase; serum cholinesterase; BChE) have been shown to exhibit prolonged muscle paralysis and apnea in response to the muscle relaxant drug, succinylcholine.l? On the other hand, the BChE activity has been used in Japan as a marker of liver dysfunction, because BChE is mainly produced in the liver. Thus genetic variants of the enzyme are sometimes misdiagnosed as liver dysfunction. Conventionally, most of the serum cholinesterase variants were qualitatively identified by dibucaine number (DN) and fluoride number (FN) phenotyping."? However, during the last two decades, the discovery of several additional BChE variants has complicated the qualitative phenotyping. Several of these variants like the Hvvariant.t the Jvvariant." the Kvvariant" and some of the silent variants'''? are characterized as quantitative variants. Traditional inhibition tests are unable to discriminate between quantitative variants and the normal enzyme except for heterozygous atypical variants. Effective screening and focusing of the cases who are suspected as variants are essential for detection of such genetic mutations.
We have been investigating mutations of the BCHE gene in suspected genetic variants. A series of investigations have identified some individuals with slightly diminished DN and FN. They were detected to have the same mutation, TTA (Leu) to ATA (Ile) at codon 330 by DNA analysis.'? Here, we focused on the BCHE*3301 mutation and tried to clarify the genotype-phenotype correlation. Also we presented two novel mutations discovered in individuals with the trace activity of BChE.
MATERIALS AND METHODS

Subjects
All patients were classified into two groups for analysis.
Group A
This group includes 2375 individuals randomly gathered from outpatients and inpatients in the Hospital of Hamamatsu University School of Medicine, Shizuoka Prefecture, through routine laboratory tests.
Group B
This group includes individuals deficient in serum BCh E activity (nearly zero) collected from various laboratories in Japan. The laboratories that found such individuals by chance in routine laboratory tests informed us of their data and collected blood samples with the patients' informed consent. Hypocholinesterasernia due to hepatic dysfunction was ruled out on the basis of other biochemical data (serum albumin, total cholesterol and Q£-2 globulin concentrations being all within normal limits) and ultrasonic imaging of the liver. The effects of organophosphorus insecticides were also ruled out by the use of each patient's recent history.
These studies were performed in accordance with the Helsinki Declaration of 1975, as revised in 1983.
Measurement of serum BChE activity, DN and FN
Serum BChE activity was measured using propionylthiocholine iodide as a substrate (Aldrich, Milwaukee, WI, USA) on a Shimadzu CL-noo biochemistry analyzer (Shimadzu, Kyoto, Japan), and calculated in IUjL at 3TC. n The dibucaine number (DN) and fluoride number (FN) were also determined by the same means. DN is the percent inhibition of activity caused by 0·03 J.lmoljL of dibucaine and FN is the percent inhibition of activity caused by 4 J.lmoljL of sodium fluoride.
Polymerase chain reaction (PCR)-single strand conformation polymorphism (SSCP) analysis Genomic DNA was extracted from EDTAtreated venous blood using the slightly modified procedure of Kunkel et al. 14 Protein-coding exons of the BCHE gene were amplified separately by the PCR. 9 Since exon 2 is very large for SSCP analysis, it was divided into seven overlapping fragments for PCR and subsequent for 5 min and post-cycling extension at noc for 5 min. In case of mismatch PCR, the annealing temperature was 59°C (BCHE*446 V, BCHE*45IX), 50°C (BCHE*539T) or 52°C (BCHE*330/). Precautions were taken to prevent DNA contamination in either reagents or DNA samples. Amplified DNA samples showed single strong bands of the expected sizes on agarose gel electrophoresis. After PCR, each amplified product was analysed by SSCP using the Phast system (Pharmacia, Uppsala, Sweden)Ylfi PCR-amplified DNA was subjected to SSCP at 10°C for native and at 15°C for SDS conditions. One J.lL of amplified product was mixed with I J.lL of 95% formamide containing 20 mmol(L EDTA, 0·05% bromophenol blue and 0·05% xylene cyanol FF. The mixture was completely denatured by heating at 80°C for 5 min followed by snap cooling. The denatured DNA was electrophoresed in a 12·5% homogeneous gel and at 250V. Average volt hour (aVh) was adjusted according to the length of PCR product. Separated single stranded DNAs were detected using a silver staining kit purchased from Pharmacia.
Identification of mutations by restriction fragment length polymorphism (RFLP) method
Some point mutations were easily detected by digestion with restriction endonucleases because the mutation either created or abolished a known restriction site. However, in other mutations (BCHE*330!, BCHE*539T, BCHE*446V and BCHE*45IX), the mutation neither created nor destroyed any known restriction endonuclease recognition site. Those point mutations were detected by mismatched PCR. l7 The strategy of primer design and enzyme digestion for BCHE*330!, BCHE*539T are described elsewhere. 12 , 18 The sequences of mismatched primers and strategies of enzyme digestion for two new mutations, BCHE*446V and BCHE*45 IX, are shown in Figs I(a) and 2(a), respectively. For example, in the case of the T to G mutation at codon 446, a mismatched primer F-446 (5'-CTTCTTTCCAGAGGTAAACCTA-3') was synthesized, which is adjacent to the point mutation and has a mismatched A residue instead of the T in the normal allele. Theoretically, when an allele containing the TIT to GTT mutation is amplified using F-446 and common primer C2-8 (5'-TAA TTTCATATGCCCTGCCTIG-3'), the mismatched nucleotide creates a new Ddel restriction site (CTNAG) in the normal allele, which is not present in the original sequence (CTNTG). Due to another Dde! restriction site, both in normal and mutant allele, restriction endonuclease digestion of 174bp PCR product generates three fragments (111, 40 and 23 bp) in case of normal, two fragments (134 and 40 bp) in case of homozygote and 4 fragments in case of heterozygote. For the detection of G to T mutation at codon 451, a mismatched primer E-451 (5'-ATTTGTCTTIGGTTTACCTCCG-3') was synthesized, which is adjacent to the point mutation and has a mismatched C residue instead of the T in the normal allele. Theoretically, when an allele containing the GAA to TAA mutation is amplified using E-451 and common primer AP4' (5'-ACGGATCAAACCAAGCCAGAGAAC-3'), the mismatched nucleotide creates a new Mspl restriction site (CCGG) in the normal allele, which is not present in the original sequence (CTGG). Restriction endonuclease digestion of 152bp PCR product generates two fragments (132 and 20 bp) in case of normal, one undigested fragment (152 bpi in case of homozygote and 3 fragments (152,132 and 20bp) in case of heterozygote. The digested fragments were resolved on 3·5% (2'5% N uSieve low melting point agarose + I% regular) agarose gel. The enzyme digestions and subsequent analyses were done according to the instruction manual of the supplier (New England Biolabs, Beverly, MA, USA and TOYOBO, Tsuruga, Japan).
DNA sequencing
When a new mutation was suspected (due to abnormal migration pattern in SSCP), PCR amplified products were directly sequenced by dideoxy chain termination reaction using a cycle sequencing kit with an automated DNA sequencer (ABI Model 373A; Foster City, CA, USA). BGhE activity (lUlL) FIGURE For new mutations, both forward and reverse strands were sequenced and the sequencing procedure was repeated twice to exclude mutations generating from the PCR.
Dependency of BChE activity on dibucaine number (DN) andfluoride number (FN
RESULTS
Group A Screening of the patients was rather difficult as DN and FN were near the borderline of the reference interval. Furthermore, DN and FN showed a tendency dependent on cholinesterase activity. The lower the cholinesterase activity was, the lower the DN and FN were obtained. This tendency seemed to be due to the enzymatic activities of other csterases, especially arylesterase, Therefore, we plotted cholinesterase activity and DN and FN in a two-dimensional graph and picked up patients whose data were visually outside of this plotting. From a total of 2375 individuals analysed for DN and FN, we found nine individuals with slightly reduced DN and FN and I individual (No.8) with much reduced DN and FN. Figure 3 shows a plot derived from the data of 430 randomly selected individuals. Genomic DNA from the 10 patients was amplified by PCR and further analysed to determine the molecular basis of these variants. For patients I to 7, the missense mutation TTA (Leu) to ATA (lie) at codon 330 was detected by mismatch PCR followed by Dral enzyme digestion. DNA sequencing confirmed the RFLP result. For patient 8, a nonsense mutation at codon 119 CAA (Gin) to STOP (TAA) was detected readily by RFLP analysis because an Msel digestion site was created in the mutant allele. DNA sequencing (data not shown)
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supported the RFLP result. No mutation was found in patients 9 and 10 by either SSCP analysis or sequencing of all exons (2, 3 and 4) . Table I summarizes the results. Since seven out of 2375 had BCHE*3301 mutation (heterozygous), the frequency of BCHE*3301 was calculated to be more than 0·29%.
Group B
Silent variants of the BCHE mutation were suspected from a trace activity of BChE in sera. The BChE activity in parents who were putative heterozygotes was slightly lower than the reference interval, whereas it was drastically low in probands who inherited both mutant alleles from parents. We analysed three families and two individuals; other members of their family were not available ( Table 2) . PCR-SSCP analysis revealed different migration patterns in some exons. The mobility shift was observed with most of the mutated loci in single strands, and restriction endonuclease digestion could detect some of the common mutations. BCHE*365R was a frequent mutation among the selected patients as detected in three families and one unrelated individual. The remammg four alleles, BCHE*250P, BCHE*3301, BCHE*446V and BCHE*451X, were detected in only one family or individual (among the patients of Table 2 ). With BCHE*446V and BCHE*451X, the band of the amplified locus 7 in exon 2 was normal in SSCP, whereas a shift was observed in the double-strand conformation. This is due to the formation of homo-and heteroduplexes between the normal and mutant strands (data not shown). These found two novel mutations that were identified by direct DNA sequencing ( Figs  Ic and 2c) . Patient 20 was a compound heterozygote for two mutations. One was a substitution of G for T at codon 446 or amino acid replacement of phenylalanine (TTT) by valine (GTT), and the other was a common point mutation BCHE*365R. Patient 21 was also a compound heterozygote with two different mutations. One was a novel nonsense mutation at codon 451 resulting in the substitution of TAA (STOP) for GAA (glutamic acid) codon, and the other was a common point mutation BCHE*3301. Table  2 had the enzyme of ON 64 and FN 62. DNA seq uencing of all the exons showed a missense mutation at codon 330 (BCHE*3301) and a nonsense mutation at codon 451 (BCH E*451 X). Unlike patient 8, this patient had a stop codon in place of the codon for glutamic acid downstream to the active site. It is possible that these two nonsense mutations affect the tertiary structure of the protein or that mRNA was rapidly degraded before translation. The later phenomenon is more probable for the BCHE* 119X (group A) mutation because a stop codon at the beginning of the mRNA makes it more vulnerable to degradation than at the end. But the T-CHE of patient 21 (530 IUjL) lower than that of patient 8 (3213IUjL) indicates that, besides a BCHE*451 X mutation, an additional point mutation BCHE*330! synergistically contributed to this drastic fall of T-CHE.
BChE activity was almost nil for probands of group B who inherited two mutant alleles from their parents. Their RFLP analysis revealed very easily that most of them had one of the common mutations like BCHE*250P, BCHE*365R or BCHE*539T (K-polymorphism). When the proband heterozygous for one of these common mutations exhibited no enzyme activity, another mutation was suspected at a different locus. DNA sequencing was essential in those cases. Among the various alleles, BCHE*365 Rand BCHE*1l9X have so far been reported only in Japan and designated as Japanese type alleles. I I BCH E*365 R has been found in all of the five prefectures analysed, whereas BCHE* 119X, BCHE*330! and BCHE*250P were found in two or three of the prefectures. K-polymorphism was found to be highly linked to other point mutations except for very rare cases. In cases of two novel mutations, BCHE*446V was linked with K-polymorphism, but the other (BCHE*451 X) was not. For the two novel mutations, the bands were normal in SSCP but shifted in double-stranded conformation, indi-
Mutations of the BCHE gene 309
eating formation of homo-and heteroduplexes. The information of heteroduplex formation is also valuable for mutation detection.Pv" In neither group were mutations found in the CpG dinucleotide regions. The idea that our mutations (BCHE*330! and BCHE*1I9X) do not represent polymorphism was tentatively supported by our analysis by the PCR-RFLP method of 50 normal individuals randomly selected from the population. This showed nobody harbouring these mutations in accordance with their normal phenotypic profile (ON, FN).
